All In Biotech

Drug Trial Radar · NCT04053387

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults

Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

763

Actual

Start

Aug 13, 2019

Primary completion

Apr 6, 2021

Study completion Apr 6, 2021

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
Collaborators
IQVIA Biotech
First posted
Aug 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.

Conditions

  • Plaque Psoriasis

Interventions

  • tapinarof cream, 1%Drug

    Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Adverse Events and Serious Adverse EventsTime frame: Baseline to 44 weeks
  2. Frequency of Adverse Events and Serious Adverse EventsTime frame: Baseline to 44 weeks
  3. Number of Subjects With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values and Vital SignsTime frame: Baseline to 40 weeks
  4. Remittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear)Time frame: Baseline to 44 weeks
  5. Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear)Time frame: Baseline to 44 weeks
  6. Response During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild)Time frame: Baseline to 44 weeks
  7. Remittive Effect of Treatment Success: Number of Subjects Experiencing Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE With a PGA = 0 (Clear)Time frame: Baseline to 44 weeks
  8. Change From Baseline in %BSA AffectedTime frame: Baseline to 40 weeks
  9. Percent Change From Baseline in %BSA AffectedTime frame: Baseline to 40 weeks
  10. Mean Duration (Days) of Treatment CourseTime frame: Baseline to 40 weeks
  11. Change From Baseline in Psoriasis Area and Severity Index (PASI) ScoreTime frame: Baseline to 40 weeks
  12. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) ScoreTime frame: Baseline to 40 weeks
  13. Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)Time frame: Baseline to 40 weeks
  14. Percent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)Time frame: Baseline to 40 weeks

Locations

104 sites in 2 countries. Site status is shown where the registry gives one.

  • Dermavant Investigative Site

    Birmingham, Alabama

  • Dermavant Investigative Site

    Phoenix, Arizona

  • Dermavant Investigative Site

    Bryant, Arkansas

  • Dermavant Investigative Site

    Fort Smith, Arkansas

  • Dermavant Investigative Site

    Fountain Valley, California

  • Dermavant Investigative Site

    Fremont, California

  • Dermavant Investigative Site

    Fresno, California

  • Dermavant Investigative Site

    Los Angeles, California

  • Dermavant Investigative Site

    Los Angeles, California

  • Dermavant Investigative Site

    Northridge, California

  • Dermavant Investigative Site

    Oceanside, California

  • Dermavant Investigative Site

    San Diego, California

  • Dermavant Investigative Site

    Santa Ana, California

  • Dermavant Investigative Site

    Santa Monica, California

  • Dermavant Investigative Site

    Denver, Colorado

  • Dermavant Investigative Site

    Cromwell, Connecticut

  • Dermavant Investigative Site

    Boca Raton, Florida

  • Dermavant Investigative Site

    Boynton Beach, Florida

  • Dermavant Investigative Site

    Hialeah, Florida

  • Dermavant Investigative Site

    Margate, Florida

  • Dermavant Investigative Site

    Miami, Florida

  • Dermavant Investigative Site

    Miramar, Florida

  • Dermavant Investigative Site

    Boise, Idaho

  • Dermavant Investigative Site

    Rolling Meadows, Illinois

  • Dermavant Investigative Site

    Evansville, Indiana

  • Dermavant Investigative Site

    Indianapolis, Indiana

  • Dermavant Investigative Site

    New Albany, Indiana

  • Dermavant Investigative Site

    Plainfield, Indiana

  • Dermavant Investigative Site

    Overland Park, Kansas

  • Dermavant Investigative Site

    Louisville, Kentucky

  • Dermavant Investigative Site

    Owensboro, Kentucky

  • Dermavant Investigative Site

    Baton Rouge, Louisiana

  • Dermavant Investigative Site

    New Orleans, Louisiana

  • Dermavant Investigative Site

    Rockville, Maryland

  • Dermavant Investigative Site

    Boston, Massachusetts

  • Dermavant Investigative Site

    Bay City, Michigan

  • Dermavant Investigative Site

    Clarkston, Michigan

  • Dermavant Clinical Site

    Detroit, Michigan

  • Dermavant Investigational Site

    Detroit, Michigan

  • Dermavant Investigative Site

    Fort Gratiot, Michigan

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.